Tenecteplase Drug Market Overview
The tenecteplase drug market is expected to reach USD 2,455.4 million by 2030 at 5.10% CAGR during the forecast period 2022-2030. Tenecteplase is a medication made from a human cell line using recombinant DNA technology. This enzyme is a clot-busting medication that is used to treat thrombus (blood clots). Tenecteplase is a bioengineered activase medication. The increasing cases of deep vein thrombosis, stroke, and patients with high blood pressure are the main factors impacting this industry. According to the American Heart Association, almost 790,000 Americans experience a heart attack each year. Coronary artery disease is on the rise as people's lifestyles change. These reasons boost the market for tenecteplase. However, the market expansion is projected to be limited by issues such as the high cost of surgical treatments, allergic reactions, and pharmacological side effects. There is a demand for novel and safe stroke treatment due to the large number of stroke patients worldwide.
Anti-platelets, anti-coagulants, and anticonvulsants are used to treat stroke patients. Because of the rising advancements in clinical practice, myocardial infection, and availability of stroke therapy in this region, it is estimated that North America led the global Tenecteplase Drug Market. Due to an increase in stroke events, Europe ranked second in the market. Asia-Pacific was predicted to be the global Tenecteplase Drug Market's fastest expanding region. Because of the rising prevalence of hypertension, changing lifestyles, and increasing heart illness in the population, the market is predicted to rise.
The global market is segmented on the basis of application, dosage and end users.
The Tenecteplase drug market, by application segmented into myocardial infarction, stroke, DVT. The Tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into an adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the basis of end-user, it is segmented into hospitals and clinics, surgical centers, research centers. On the basis of region, the global tenecteplase drug market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Some of the key players in the global tenecteplase drug market are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.
Regional Market Summary
Global Tenecteplase Drug Market Share (%), by Region, 2017
Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health
It is estimated that North America dominated the global market owing to the increasing innovations in clinical practice, myocardial infection, and access to stroke treatment in this region. According to an article published by CDC in October 2015, report 350,000 to 900,000 cases of Venous thromboembolism (VTE) are estimated every year in the US. This influences the market growth in this region.
Europe stood second largest in the market due to increase in the incidents of stroke. According to UK stroke, Organization stroke is the 10th leading cause of death in the world, 34,883 mortality cases of stroke found in the UK in 2015. Due to an increase in hypertension and high blood pressure, the cases of stroke are increasing which can be a major reason for increasing the market in this region.
Asia-Pacific was projected to be the fastest growing region for the global market in 2017. The market is expected to witness growth owing to the rising prevalence of hypertension, changing lifestyle, and increasing cardiac disease in the population. According, to the Australian Bureau of Statistics 2015, 4.1 million Australians had high blood pressure. Such a high incidence of high blood pressure favors the market growth in this region.
The Middle East and Africa holds the least share of the global tenecteplase drug market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
Market Segmentation and Key Market Players
Global Tenecteplase Drug Market, by Application
Global Tenecteplase Drug Market, by Dosage
Global Tenecteplase Drug Market, by End-User
Global Tenecteplase Drug Market, by Region
|Market Size||USD 2,455.4 million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Application, Dosage And End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc|
|Key Market Opportunities||
|Key Market Drivers||
Tenecteplase drug market growth would be affected due to high surgical costs, allergic reactions, and side-effects.
The applications included in tenecteplase drug market report are myocardial infarction, stroke, and DVT.
Dosage mentioned in teneteplase drug market is intravenous dosage and intracatheter instillation dosage.
The included end users are hospitals & clinics, surgical centers, and research centers.
The players involved in the tenecteplase drug market are Gennova Pharmaceutical, Boehringer Ingelheim International GmbH, Emcure Pharmaceutical, Merck Ltd. Genentec Inc., Hisun USA, Rewine Pharmaceuticals, and Crunchbase Inc., and others.